Pages that link to "Q48333460"
Jump to navigation
Jump to search
The following pages link to Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism (Q48333460):
Displayed 31 items.
- Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates (Q26852311) (← links)
- Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? (Q34044620) (← links)
- The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies (Q34120740) (← links)
- Pathophysiology of levodopa-induced dyskinesia: potential for new therapies (Q34325365) (← links)
- Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements (Q35932567) (← links)
- Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa (Q36085612) (← links)
- Comparative Ultrastructural Analysis of D1 and D5 Dopamine Receptor Distribution in the Substantia Nigra and Globus Pallidus of Monkeys (Q37342898) (← links)
- Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys (Q37398168) (← links)
- Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review (Q37838858) (← links)
- Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. (Q37924629) (← links)
- Non-human primate models of PD to test novel therapies (Q39229450) (← links)
- Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients (Q41566638) (← links)
- Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats (Q41582688) (← links)
- Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex (Q42277740) (← links)
- Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. (Q42540026) (← links)
- Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys (Q42552539) (← links)
- Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease (Q43540752) (← links)
- The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. (Q44668514) (← links)
- Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. (Q45130529) (← links)
- Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study (Q46580727) (← links)
- Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations (Q46971688) (← links)
- Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution (Q48147364) (← links)
- A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease (Q48199227) (← links)
- Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine (Q48229063) (← links)
- Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. (Q48241892) (← links)
- Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. (Q48361936) (← links)
- Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis (Q48678048) (← links)
- L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset (Q64767857) (← links)
- Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study (Q71605674) (← links)
- Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys (Q73190000) (← links)
- Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment (Q73897941) (← links)